Aehr Test Systems, identified by its NASDAQ ticker AEHR, saw its shares decline notably during Thursday's extended trading session following the release of its second-quarter earnings report. The stock movement occurred primarily in reaction to quarterly results that revealed revenue below analyst consensus, despite earnings that met expectations.
In detail, Aehr Test Systems disclosed a quarterly loss of $0.04 per share, closely matching the consensus forecasts from market analysts. However, when it comes to revenue, the company faced challenges; quarterly top-line revenue measured $9.88 million. This figure represents a 14.72% shortfall relative to analysts' projection of $11.59 million and also indicates a decrease from $13.45 million in revenue recorded during the same quarter a year ago.
The shortfall in revenue has driven caution among investors, resulting in a near 8% drop in AEHR's share price during the extended trading session. Specifically, data shows the stock fell approximately 7.75%, reaching $20.94 per share following the earnings release.
Looking closer at sales dynamics, Aehr Test Systems reported new bookings totaling $6.2 million for the quarter. Moreover, the backlog was reported at $11.8 million as of November 28, 2025. When accounting for bookings received subsequent to that date, the company’s effective backlog rose to $18.3 million, reflecting a stronger order position than the official backlog alone would suggest.
From a strategic perspective, the company's chief executive officer, Gayn Erickson, acknowledged the quarter's revenue shortfall but remained optimistic. Erickson emphasized significant strides made in two core areas of business technology: the wafer-level burn-in (WLBI) and packaged-part burn-in (PPBI) segments. He expressed enthusiasm about the potential those business lines hold for future growth, projecting continued progress despite current headwinds.
The stock's decline was captured in market analysis tools, with Benzinga Pro noting the percentage drop and current pricing following the earnings announcement. Overall, Aehr Test Systems is navigating a quarter of mixed results, constrained by lower-than-anticipated revenue but buoyed by earnings alignment and backlog development.
While the company faces short-term pressures reflected in its quarterly sales and subsequent stock reactions, the focused advancements in niche technological segments signal areas where Aehr is investing for sustained competitive advantage. How these evolving dynamics will play out in future quarters remains contingent on execution and external market conditions.